Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized comparison of prolonged-release octreotide acetate C2L-OCT-01 PR vs Sandostatin LAR in acromegaly
2006-005855-14Phase 3Completed
- Sponsor
- Ambrilia Biopharma Inc.
- Start
- Nov 2006
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of octreotide in acromegaly (2 arms), sponsored by Ambrilia Biopharma Inc. Primary endpoints: Mean serum IGF-1 concentration and Mean serum growth hormone concentration. Started Nov 2006; status: completed.
02
Drugs
octreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2006-005855-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005855-14.